{"id":39029,"date":"2026-07-06T11:10:00","date_gmt":"2026-07-06T15:10:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39029"},"modified":"2026-05-20T11:12:08","modified_gmt":"2026-05-20T15:12:08","slug":"pat-informed-for-drug-patent-loe-dates-what-it-can-and-cannot-tell-you","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/pat-informed-for-drug-patent-loe-dates-what-it-can-and-cannot-tell-you\/","title":{"rendered":"PAT-INFORMED for Drug Patent LOE Dates: What It Can (and Cannot) Tell You"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

The short answer is: yes, you can use PAT-INFORMED to find drug patent information, including grant dates and expiry dates \u2014 but only for a limited scope of products, only for the patents that participating companies chose to submit, and without the regulatory exclusivity data that makes a Loss-of-Exclusivity (LOE) date commercially meaningful.<\/p>\n\n\n\n

That distinction matters. LOE analysis in pharmaceutical strategy is not the same as reading a patent expiry date off a registry. True LOE dates require stacking patent expiry, Patent Term Extension (PTE), regulatory exclusivity codes, Paragraph IV challenge status, and active litigation outcomes into a single defensible number. PAT-INFORMED gives you one layer of that stack. Knowing what that layer is \u2014 and what it is not \u2014 determines whether you use the tool correctly or build an analysis on a gap.<\/p>\n\n\n\n

This guide covers how PAT-INFORMED works, what data it actually contains, which professionals it was designed for, and where it falls short for U.S.-focused pharmaceutical competitive intelligence. It also sets out the alternative and complementary resources that practitioners rely on when LOE precision is the goal.<\/p>\n\n\n\n

\n\n\n\n

What Is PAT-INFORMED? The WIPO-IFPMA Patent Database Explained<\/strong><\/h2>\n\n\n\n

PAT-INFORMED stands for Patent Information Initiative for Medicines. It is a free, open-access database launched in September 2018 as a partnership between the World Intellectual Property Organization (WIPO) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), with voluntary participation from 20 research-based pharmaceutical companies at launch.<\/p>\n\n\n\n

The database lets anyone search by INN (International Nonproprietary Name) \u2014 the generic drug name \u2014 and retrieve patent numbers, publication dates, grant dates, and grant numbers for participating jurisdictions around the world. WIPO hosts the data and links records to its PATENTSCOPE database where possible. The companies provide and update their own records directly.<\/p>\n\n\n\n

Who Built PAT-INFORMED and Why It Exists<\/strong><\/h3>\n\n\n\n

The initiative originated from a specific problem that has nothing to do with U.S. pharmaceutical competitive intelligence. Most countries outside the United States do not maintain a public registry linking approved medicines to their patents. The U.S. Orange Book solves this domestically. No equivalent existed globally before 2018.<\/p>\n\n\n\n

Without a centralized reference, procurement agencies in developing countries could not easily determine whether a medicine they wanted to purchase was still under patent in their country \u2014 information they need to decide whether to seek a generic supplier or buy from the brand. That uncertainty slowed procurement cycles and increased medicine costs in markets that could least afford the inefficiency.<\/p>\n\n\n\n

\n

‘This initiative is a practical way of reducing the complexity around access to patent information, something health experts have long been calling for. It will help governments make better informed decisions about procurement options available to them.’ \u2014 Thomas Cueni, IFPMA Director General, September 2018 launch [1]<\/p>\n<\/blockquote>\n\n\n\n

Wesley Kreft of i+solutions, a Netherlands-based NGO specializing in medicines procurement for developing countries, estimated at launch that PAT-INFORMED had the potential to reduce the procurement process by 30% for agencies using it [2].<\/p>\n\n\n\n

That is the use case PAT-INFORMED was designed to serve. Understanding this origin clarifies almost everything about the database’s strengths and limitations.<\/p>\n\n\n\n

Which Companies Participate in PAT-INFORMED?<\/strong><\/h3>\n\n\n\n

At launch, 20 major research-based pharmaceutical companies agreed to voluntarily provide patent information through the platform. These companies also committed to respond to follow-up inquiries from procurement agencies \u2014 a second-tier service within the database reserved for verified bona fide procurement organizations.<\/p>\n\n\n\n

Participating companies included members of IFPMA’s global membership base: large multinational innovators across U.S., European, and Japanese markets. The data reflects what each company chose to submit, not an independently verified complete patent landscape. That self-reported structure is a fundamental design feature, not a flaw \u2014 but it shapes how the data should be interpreted.<\/p>\n\n\n\n

What Therapeutic Areas Does PAT-INFORMED Cover?<\/strong><\/h3>\n\n\n\n

The current scope covers small-molecule drugs in six therapeutic areas: HIV\/AIDS, cardiovascular disease, diabetes, hepatitis C, oncology, and respiratory conditions. Products on the WHO Essential Medicines List (EML) that fall outside these six areas are also included.<\/p>\n\n\n\n

The database covers 169 International Non-proprietary Names (INNs), 600 patent families, and over 14,000 individual patents as of the most recent IFPMA data [3]. A second phase of the initiative planned to extend coverage to all therapeutic areas and explore inclusion of complex therapeutics (biologics), but that expansion has not been fully completed as of 2026.<\/p>\n\n\n\n

The practical implication: if you need LOE data on a central nervous system drug, a musculoskeletal product, a dermatology compound, or virtually any biologic, PAT-INFORMED will not help you. The coverage footprint is meaningful for global procurement of essential medicines in a narrow set of disease areas. It is narrow for pharmaceutical competitive intelligence in most commercial contexts.<\/p>\n\n\n\n

PAT-INFORMED Therapeutic Coverage at a Glance<\/strong><\/h4>\n\n\n\n
Therapeutic Area<\/strong><\/th>Covered by PAT-INFORMED?<\/strong><\/th>Orange Book Equivalent?<\/strong><\/th><\/tr><\/thead>
HIV\/AIDS<\/td>Yes<\/td>Yes (U.S. only)<\/td><\/tr>
Hepatitis C<\/td>Yes<\/td>Yes (U.S. only)<\/td><\/tr>
Oncology<\/td>Yes<\/td>Yes (U.S. only)<\/td><\/tr>
Cardiovascular<\/td>Yes<\/td>Yes (U.S. only)<\/td><\/tr>
Diabetes<\/td>Yes<\/td>Yes (U.S. only)<\/td><\/tr>
Respiratory<\/td>Yes<\/td>Yes (U.S. only)<\/td><\/tr>
WHO Essential Medicines (other)<\/td>Yes<\/td>Yes (U.S. only)<\/td><\/tr>
CNS\/Neurology<\/td>No<\/td>Yes (U.S. only)<\/td><\/tr>
Dermatology<\/td>No<\/td>Yes (U.S. only)<\/td><\/tr>
Musculoskeletal<\/td>No<\/td>Yes (U.S. only)<\/td><\/tr>
Biologics\/Biosimilars<\/td>No (planned, not implemented)<\/td>Purple Book (U.S. only)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
\n\n\n\n

How to Search PAT-INFORMED: Step-by-Step<\/strong><\/h2>\n\n\n\n

The search interface is straightforward. Navigate to wipo.int\/pat-informed, type the INN of the drug you are researching into the search bar, and select the relevant country from the jurisdiction filter.<\/p>\n\n\n\n

What PAT-INFORMED Search Results Actually Show You<\/strong><\/h3>\n\n\n\n

Results appear as cards grouped by patent family. Each card for a given jurisdiction shows:<\/p>\n\n\n\n

    \n
  • Patent publication number and publication date<\/li>\n\n\n\n
  • Grant number and grant date<\/li>\n\n\n\n
  • A link to the patent text in WIPO’s PATENTSCOPE database where available<\/li>\n\n\n\n
  • Contact information for the company holding the patent<\/li>\n<\/ul>\n\n\n\n

    The grant date, combined with the 20-year statutory patent term, lets you calculate a nominal expiry date for that jurisdiction. This is the closest PAT-INFORMED comes to displaying LOE information directly.<\/p>\n\n\n\n

    The Two-Tier System: Public Database vs. Procurement Agency Inquiries<\/strong><\/h3>\n\n\n\n

    PAT-INFORMED has two functional layers. The first is the public database \u2014 searchable by anyone. The second layer is an inquiry mechanism where verified procurement agencies can contact the patent-holding company directly for additional information.<\/p>\n\n\n\n

    This second tier exists because some patent questions require context that no database can pre-populate: pending patent applications not yet granted, national-phase filing status in specific jurisdictions, or patent assignments following mergers. Company responses through this channel are not confidential, meaning answers can inform public procurement decisions transparently.<\/p>\n\n\n\n

    For commercial pharmaceutical intelligence professionals \u2014 brand managers, business development analysts, hedge fund analysts \u2014 this second tier is effectively inaccessible. It targets WHO, UNICEF, government health ministries, and NGO procurement units.<\/p>\n\n\n\n

    How to Access PAT-INFORMED’s Procurement Inquiry Channel<\/strong><\/h4>\n\n\n\n

    Verified procurement agencies submit requests through the PAT-INFORMED platform, where WIPO and IFPMA act as intermediaries forwarding the inquiry to the relevant company. The company’s response is not confidential. There is no defined response time guarantee, but participating companies committed at launch to responding to bona fide requests.<\/p>\n\n\n\n

    Proof of procurement agency status \u2014 typically organizational credentials establishing government, intergovernmental, or recognized NGO procurement function \u2014 is required before the inquiry channel activates. Private-sector queries will not receive company responses through this mechanism.<\/p>\n\n\n\n

    \n\n\n\n

    Does PAT-INFORMED Show Loss-of-Exclusivity Dates Directly?<\/strong><\/h2>\n\n\n\n

    No. PAT-INFORMED does not display a ‘Loss of Exclusivity date’ field. What it shows are patent grant dates, publication dates, and grant numbers. From those inputs, a user can calculate a theoretical patent expiry date for a given country by adding 20 years from the filing date or applying the relevant national patent term. That calculation is not automatic within the interface.<\/p>\n\n\n\n

    Why a Patent Expiry Date Is Not the Same as an LOE Date<\/strong><\/h3>\n\n\n\n

    This is the central analytical gap that distinguishes PAT-INFORMED from tools built specifically for pharmaceutical LOE intelligence. A true LOE date is determined by whichever of the following expires last:<\/p>\n\n\n\n

      \n
    • The last-to-expire Orange Book-listed patent (U.S. context)<\/li>\n\n\n\n
    • Any applicable Patent Term Extension granted under 35 U.S.C. \u00a7 156<\/li>\n\n\n\n
    • Regulatory exclusivity periods (New Chemical Entity exclusivity, Orphan Drug Exclusivity, pediatric exclusivity extensions)<\/li>\n\n\n\n
    • Any active 30-month litigation stay triggered by a Paragraph IV ANDA filing<\/li>\n\n\n\n
    • Settlement agreements that define an authorized generic entry date earlier than patent expiry<\/li>\n<\/ul>\n\n\n\n

      PAT-INFORMED provides data relevant only to the first element, and only partially \u2014 it shows company-submitted key patents, not every listed Orange Book patent. It shows nothing about regulatory exclusivity periods, PTEs, Paragraph IV certifications, ANDA filings, litigation status, or settlement outcomes.<\/p>\n\n\n\n

      Patent Term Extensions: What PAT-INFORMED Misses for U.S. LOE Analysis<\/strong><\/h3>\n\n\n\n

      In the United States, a pharmaceutical company can apply for a Patent Term Extension (PTE) under the Hatch-Waxman Act to compensate for time lost to FDA regulatory review. PTEs can add up to five years to a patent’s term, with a maximum extended term of 14 years from FDA approval. This means a drug’s effective patent protection can run years beyond its nominal 20-year term.<\/p>\n\n\n\n

      PAT-INFORMED records show grant dates, not PTE-adjusted expiry dates. If a composition-of-matter patent on a major branded drug was filed in 2000, granted in 2002, and received a five-year PTE based on an eight-year FDA review, its actual enforceable expiry is 2027 \u2014 not 2020. Using the grant date plus 20 years from filing would give you a nominal expiry of 2020 and a completely wrong LOE estimate.<\/p>\n\n\n\n

      For U.S.-focused LOE work, the Orange Book is the authoritative source for PTE-adjusted expiry dates and regulatory exclusivity data.<\/p>\n\n\n\n

      \n\n\n\n

      PAT-INFORMED vs. FDA Orange Book: Which Tool for Which Question?<\/strong><\/h2>\n\n\n\n

      These two databases address related but distinct questions. Conflating them produces analytical errors.<\/p>\n\n\n\n

      Side-by-Side Comparison: PAT-INFORMED vs. Orange Book<\/strong><\/h3>\n\n\n\n
      Feature<\/strong><\/th>PAT-INFORMED<\/strong><\/th>FDA Orange Book<\/strong><\/th><\/tr><\/thead>
      Geographic scope<\/td>Global (multi-jurisdiction per drug)<\/td>United States only<\/td><\/tr>
      Patent expiry dates<\/td>Calculable from grant date + statutory term<\/td>Listed directly, PTE-adjusted<\/td><\/tr>
      Regulatory exclusivity<\/td>Not included<\/td>Fully listed with codes and expiry dates<\/td><\/tr>
      Paragraph IV certifications<\/td>Not included<\/td>Tracked separately via ANDA filing records<\/td><\/tr>
      Biologic coverage<\/td>Planned but limited as of 2026<\/td>Purple Book for biologics (separate)<\/td><\/tr>
      Therapeutic area coverage<\/td>Six areas + WHO EML<\/td>All FDA-approved prescription drugs<\/td><\/tr>
      Data source<\/td>Company-submitted, self-reported<\/td>Company-submitted, FDA-verified format<\/td><\/tr>
      Litigation data<\/td>None<\/td>None (requires separate federal court dockets)<\/td><\/tr>
      Primary user<\/td>Procurement agencies, global health bodies<\/td>Generic manufacturers, brand companies, attorneys<\/td><\/tr>
      Cost<\/td>Free<\/td>Free<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      When the Orange Book Fails Outside the U.S.: PAT-INFORMED’s Real Value<\/strong><\/h3>\n\n\n\n

      The Orange Book is powerful and precise for U.S. LOE analysis. It provides nothing outside the United States. If you need to determine whether sofosbuvir is still under patent in Brazil, whether tenofovir alafenamide has active patent protection in Nigeria, or whether a cardiac drug is patent-expired in Thailand, the Orange Book is useless. PAT-INFORMED was built to answer exactly those questions.<\/p>\n\n\n\n

      WIPO’s own publications describe PAT-INFORMED as ‘effectively globalizing the concept of the Orange Book’ [4] \u2014 a framing that captures the intent while overstating completeness. The Orange Book is mandatory, legally binding, and subject to FDA oversight and challenge mechanisms. PAT-INFORMED is voluntary, self-reported, and subject to no enforcement mechanism. Those differences matter when you are deciding whether to launch a generic in a given market.<\/p>\n\n\n\n

      What the Orange Book Lists That PAT-INFORMED Does Not: A Field-by-Field Breakdown<\/strong><\/h4>\n\n\n\n

      For each approved NDA product, the Orange Book publishes: the patent number; the patent expiration date adjusted for any PTE; whether the patent covers the active ingredient, formulation, or method of use; the exclusivity code (NCE, ODE, pediatric, new indication, orphan drug); and the exclusivity expiration date. The combination of patent expiration date and exclusivity expiration date defines the full legal barrier to generic ANDA approval \u2014 and neither element appears fully in PAT-INFORMED.<\/p>\n\n\n\n

      \n\n\n\n

      PAT-INFORMED vs. MedsPaL: Two Tools for Global Patent Access<\/strong><\/h2>\n\n\n\n

      MedsPaL, hosted by the Medicines Patent Pool (MPP), is the other major global patent access database. The two tools are frequently compared and address overlapping but distinct aspects of global medicine access.<\/p>\n\n\n\n

      MedsPaL vs. PAT-INFORMED: Data Source and Coverage Differences<\/strong><\/h3>\n\n\n\n

      The fundamental difference is data origin. PAT-INFORMED relies entirely on patent information submitted voluntarily by participating brand companies. MedsPaL gathers data from national and regional patent offices, combines it with licensing information from public licensing agreements, and adds data exclusivity information from national regulatory authorities [5].<\/p>\n\n\n\n

      This means MedsPaL can include patent status information for drugs whose manufacturers did not participate in PAT-INFORMED, drawing on official patent office records rather than self-reporting. However, MedsPaL focuses on a narrower drug list: HIV, tuberculosis, hepatitis C, and other patented essential medicines in low- and middle-income countries.<\/p>\n\n\n\n

      A procurement agency researching hepatitis C drugs for a middle-income country has reason to check both databases. PAT-INFORMED may provide more company-specific detail and offer the direct inquiry channel to the brand. MedsPaL may provide broader national patent office coverage and licensing context. Neither replaces the other entirely.<\/p>\n\n\n\n

      Medicines Patent Pool Voluntary Licensing vs. PAT-INFORMED Patent Status Data<\/strong><\/h3>\n\n\n\n

      The Medicines Patent Pool (MPP) negotiates voluntary licensing agreements with brand pharmaceutical companies that allow generic manufacturers in low- and middle-income countries to produce and sell patented drugs. When an MPP licensing agreement covers a drug in a specific country, the active patent status in that country is commercially irrelevant for licensed generic manufacturers \u2014 they can produce regardless of patent status because they have a license.<\/p>\n\n\n\n

      MedsPaL integrates this licensing data, which means a procurement agency using MedsPaL can see not just whether a patent exists but whether a voluntary license has already been negotiated that removes the barrier. PAT-INFORMED shows patent status but not licensing status. For procurement decisions in markets covered by MPP agreements, MedsPaL provides more commercially actionable information.<\/p>\n\n\n\n

      \n\n\n\n

      What PAT-INFORMED Can and Cannot Tell a U.S. Pharmaceutical Analyst<\/strong><\/h2>\n\n\n\n

      Legitimate Use Cases for U.S. Analysts<\/strong><\/h3>\n\n\n\n

      PAT-INFORMED is genuinely useful to U.S.-based professionals working on global market access, international lifecycle management, or generics strategy in non-U.S. markets. Specific use cases include:<\/p>\n\n\n\n

        \n
      • Checking whether a composition-of-matter patent has been granted in a specific emerging market before committing to a tender or partnership<\/li>\n\n\n\n
      • Identifying which patent families a company has filed globally for a given INN, as a starting point for freedom-to-operate analysis in non-U.S. jurisdictions<\/li>\n\n\n\n
      • Cross-referencing company-submitted patent family data against PATENTSCOPE to identify PCT application chains<\/li>\n\n\n\n
      • Obtaining a quick-reference grant date for a major jurisdiction where you need a rough patent expiry estimate without a full patent landscape search<\/li>\n<\/ul>\n\n\n\n

        What PAT-INFORMED Cannot Do for LOE Modeling<\/strong><\/h3>\n\n\n\n

        For U.S.-focused LOE modeling, generic entry forecasting, ANDA strategy, or financial analysis of branded pharmaceutical revenue at risk, PAT-INFORMED is insufficient as a primary source. Specific gaps include:<\/p>\n\n\n\n

          \n
        • No listing of regulatory exclusivities (NCE exclusivity, ODE, pediatric extensions)<\/li>\n\n\n\n
        • No PTE-adjusted expiry dates<\/li>\n\n\n\n
        • No Paragraph IV certification tracking<\/li>\n\n\n\n
        • No 30-month stay analysis<\/li>\n\n\n\n
        • No coverage of method-of-use or formulation patents beyond company-selected key patents<\/li>\n\n\n\n
        • No biologics coverage in practice<\/li>\n\n\n\n
        • No settlement agreement data<\/li>\n<\/ul>\n\n\n\n

          A revenue model built using PAT-INFORMED as its primary patent expiry source will contain systematic errors. As DrugPatentWatch’s competitive intelligence analysis notes, a flawed patent expiration date produces a flawed LOE model \u2014 and financial models that compound a single incorrect date across multi-year revenue projections multiply that error significantly [6].<\/p>\n\n\n\n

          \n\n\n\n

          How Drug Patent Loss-of-Exclusivity Dates Are Actually Calculated<\/strong><\/h2>\n\n\n\n

          Understanding the actual methodology clarifies why PAT-INFORMED covers only one element of the calculation.<\/p>\n\n\n\n

          The Five-Layer LOE Stack: From Patent Filing to Generic Entry Date<\/strong><\/h3>\n\n\n\n

          Layer 1: Composition-of-Matter (CoM) Patent Expiry.<\/strong> The CoM patent on the active ingredient is typically the most important. Filed early in development \u2014 often at the preclinical stage \u2014 it runs 20 years from filing. Because FDA approval takes 10-15 years post-filing on average, the effective post-approval market exclusivity from the CoM patent alone is often five to ten years [7].<\/p>\n\n\n\n

          Layer 2: Patent Term Extension (PTE).<\/strong> A single PTE can extend one patent per product by up to five years under 35 U.S.C. \u00a7 156, compensating for time lost in FDA review. The PTE-adjusted expiry, not the raw filing-date-plus-20-years figure, is what Orange Book listings reflect.<\/p>\n\n\n\n

          Layer 3: Regulatory Exclusivities.<\/strong> New Chemical Entity (NCE) exclusivity gives five years of protection from any ANDA filing (other than Paragraph IV challenges starting at year four). Orphan Drug Exclusivity (ODE) provides seven years. Pediatric exclusivity adds six months to all existing patents and exclusivities upon completion of a pediatric study. These can outlast patents or provide protection even when patents are challenged successfully.<\/p>\n\n\n\n

          Layer 4: Secondary Patent Landscape.<\/strong> Method-of-use patents, formulation patents, polymorphic form patents, and process patents extend beyond CoM expiry for most major drugs. Orange Book listing is required for patents that could trigger Hatch-Waxman litigation. An ANDA filer must certify against every listed patent.<\/p>\n\n\n\n

          Layer 5: Litigation and Settlement Outcomes.<\/strong> A successful Paragraph IV challenge can allow generic entry before every listed patent expires. Conversely, serial litigation using continuation patents can reset the clock repeatedly. Settlement agreements frequently set authorized generic entry dates independent of both patent expiry and litigation outcomes.<\/p>\n\n\n\n

          Why the ‘True’ LOE Date Changes Over Time<\/strong><\/h3>\n\n\n\n

          LOE dates are not static. A PTAB Inter Partes Review decision can invalidate a key formulation patent within months. A new Paragraph IV certification by a generic filer resets the litigation timeline. A post-approval pediatric study that earns exclusivity adds six months to every existing protection on the product. A settlement that grants authorized generic rights to a specific generic company on a specific date supersedes every other date in the model.<\/p>\n\n\n\n

          Tools that display patent grant data without continuous litigation and regulatory monitoring \u2014 PAT-INFORMED and the Orange Book itself both have this limitation \u2014 show a static photograph of a moving target.<\/p>\n\n\n\n

          \n\n\n\n

          The PTAB Factor: How Inter Partes Review Alters LOE Analysis<\/strong><\/h2>\n\n\n\n

          The Patent Trial and Appeal Board (PTAB), created by the America Invents Act of 2011, introduced a post-grant review mechanism that has reshaped pharmaceutical patent strategy \u2014 and created an entirely new category of LOE risk that no static patent database can capture.<\/p>\n\n\n\n

          PTAB IPR Institution Rates for Pharmaceutical Patents: 2024-2025 Statistics<\/strong><\/h3>\n\n\n\n

          In fiscal year 2024, 73% of bio\/pharma IPR petitions filed at the PTAB were instituted \u2014 a higher rate than the 68% overall institution rate across all technology sectors [14]. Once instituted, pharmaceutical patent challenges result in all claims being cancelled at a high rate. In FY2024, the all-claims invalidation rate across all technology sectors was 70%, dropping slightly to 64% in the first half of FY2025 [15].<\/p>\n\n\n\n

          A composition-of-matter patent on a $5 billion drug that survives until its 2029 expiry date represents a very different NPV than the same patent invalidated at the PTAB in 2026. The delta between those two scenarios can exceed $10 billion in revenue for the patent holder [16].<\/p>\n\n\n\n

          In FY2025 through August, the PTAB received 1,339 total petitions, of which bio\/pharma patents accounted for 7% (approximately 94 petitions) [17]. These are concentrated in high-value products approaching LOE \u2014 the economic incentive for a successful IPR on a blockbuster drug is enormous for both generic manufacturers and non-practicing entities.<\/p>\n\n\n\n

          How PTAB Decisions Change LOE Dates: Practical Implications<\/strong><\/h3>\n\n\n\n

          When the PTAB cancels claims in a pharmaceutical patent, the generic manufacturer petitioning for IPR gains freedom to operate \u2014 if it was also an ANDA filer with a Paragraph IV challenge in the district court, the PTAB cancellation decision typically resolves the litigation in the generic’s favor. The ANDA can become effective immediately, subject to any remaining regulatory exclusivity period.<\/p>\n\n\n\n

          The critical point for LOE analysts: PTAB outcomes that move LOE dates happen on a litigation calendar that bears no relation to any patent expiry date in any database. A patent with a 2031 nominal expiry can have its commercially effective LOE moved to 2025 by a successful IPR in 2024. No version of PAT-INFORMED, the Orange Book, or any static patent registry will show this until after it happens.<\/p>\n\n\n\n

          Only active monitoring of PTAB petition dockets \u2014 which IPR petitions have been filed against which patents on which drugs, which have been instituted, and where each proceeding stands in its timeline \u2014 provides advance warning of LOE date shifts driven by PTAB activity.<\/p>\n\n\n\n

          Serial Litigation and How It Delays Generic Entry Beyond Patent Expiry<\/strong><\/h3>\n\n\n\n

          A documented litigation tactic in Hatch-Waxman cases involves brand companies filing successive lawsuits based on continuation patents \u2014 new but substantively indistinguishable from patents already challenged in prior litigation. Researchers studying this phenomenon identified the pattern in multiple drugs, including Astellas’s overactive bladder drug mirabegron (Myrbetriq), where an initial Hatch-Waxman case settled in 2020 with generic entry expected in 2024, followed by four additional lawsuits built on new continuation patents that delayed broad competition and resulted in only two firms launching in 2024 under threat of massive damages [18].<\/p>\n\n\n\n

          Similar patterns appeared with bimatoprost (Latisse), aflibercept (Eylea), and tasimelteon (Hetlioz) [18]. Each serial lawsuit, even if ultimately unsuccessful, triggers a new 30-month stay. Multiple consecutive stays can extend the effective LOE date by years beyond any individual patent’s nominal expiry.<\/p>\n\n\n\n

          From a database perspective, each new continuation patent listing in the Orange Book creates a new Paragraph IV filing obligation for generic filers \u2014 a new data event that must be tracked and monitored. PAT-INFORMED will not capture these continuations. The Orange Book will list them only after they are submitted by the NDA holder within the required 30-day window.<\/p>\n\n\n\n

          \n\n\n\n

          The PAT-INFORMED Data Quality Problem: Self-Reporting and Coverage Gaps<\/strong><\/h2>\n\n\n\n

          Who Decides Which Patents Get Submitted to PAT-INFORMED?<\/strong><\/h3>\n\n\n\n

          Participating companies submit their own patent data. The database states explicitly that it ‘relies exclusively on patent information provided by participating companies’ [5]. WIPO hosts the data but does not independently verify it against patent office records or cross-reference it for completeness.<\/p>\n\n\n\n

          This creates a potential selection effect. A company submitting patent data for PAT-INFORMED will logically submit the patents most relevant to demonstrating their product is protected \u2014 typically composition-of-matter patents with long remaining terms. Secondary patents that a company might prefer not to publicize, pending applications, or patents with contested validity may not be submitted. The database represents a curated selection of company-preferred disclosures, not a complete patent landscape.<\/p>\n\n\n\n

          Coverage Gaps by Geography: Which Countries Have Reliable Data?<\/strong><\/h3>\n\n\n\n

          PAT-INFORMED’s national coverage varies significantly by jurisdiction. For major markets where participating companies have sought patent protection \u2014 the United States, European Union, Japan, China \u2014 patent family data tends to be more complete. For smaller markets, data depends on whether the company filed in that jurisdiction and chose to submit that filing to PAT-INFORMED.<\/p>\n\n\n\n

          A company may hold an important product and have deliberately chosen not to file a patent in a given low-income country \u2014 a voluntary decision to allow generic competition in that market. PAT-INFORMED would show no patent data for that country, which accurately reflects no patent protection there. But the absence of data in PAT-INFORMED does not by itself tell you whether a patent is absent because it was never filed, because it was filed and rejected, or because it exists and simply was not submitted.<\/p>\n\n\n\n

          How to Handle Absence of Data in PAT-INFORMED<\/strong><\/h4>\n\n\n\n

          When PAT-INFORMED returns no results for a given INN in a specific country, the correct interpretation is: this product is either not covered by the initiative’s therapeutic scope, the company chose not to submit patent data for this jurisdiction, or no patent was ever sought there. It is not safe to conclude from a null result that a drug is unpatented in that country without verification against the national patent office registry or through the PAT-INFORMED inquiry channel.<\/p>\n\n\n\n

          For procurement purposes, a null PAT-INFORMED result should trigger a follow-up inquiry to the company if the drug is within the initiative’s scope \u2014 not a default assumption of patent-free status.<\/p>\n\n\n\n

          \n\n\n\n

          DrugPatentWatch and the Professional LOE Intelligence Standard<\/strong><\/h2>\n\n\n\n

          For U.S. pharmaceutical professionals who need integrated LOE analysis \u2014 the kind that combines Orange Book patent data, regulatory exclusivities, PTE calculations, Paragraph IV filing status, ANDA applicant counts, and litigation docket tracking \u2014 DrugPatentWatch is the purpose-built alternative to manual multi-source research.<\/p>\n\n\n\n

          What DrugPatentWatch Provides That PAT-INFORMED Does Not<\/strong><\/h3>\n\n\n\n

          DrugPatentWatch, operated by thinkBiotech LLC, aggregates and cross-references data from the FDA Orange Book, USPTO, federal court dockets, and FDA ANDA approval databases. Its core output for LOE analysis includes estimated generic entry dates, 180-day first-filer exclusivity tracking, NCE-1 patent challenge dates, tentative approval tracking for identifying first generic entrants, and alert monitoring for changes to any of these data points.<\/p>\n\n\n\n

          The commercial value proposition is integrating what would otherwise require manual cross-referencing across at least four government databases and continuous monitoring of federal district court filings. As DrugPatentWatch’s own analysis notes, determining the true LOE date for a drug requires manually cross-referencing a USPTO patent record against the Orange Book for PTE status, checking for overlapping regulatory exclusivities, and searching federal court dockets for active Paragraph IV litigation \u2014 a process that is time-consuming and susceptible to error without integrated tooling [8].<\/p>\n\n\n\n

          How Generic Manufacturers Use LOE Intelligence vs. Brand Manufacturers<\/strong><\/h3>\n\n\n\n

          The same LOE data serves opposite strategic purposes depending on who holds it. A generic manufacturer uses it to identify ANDA filing opportunities: when does NCE-1 open for a Paragraph IV challenge? Which products have the fewest active Paragraph IV filers ahead of them in the queue? Which 180-day exclusivity periods are about to expire, opening unrestricted generic competition?<\/p>\n\n\n\n

          A brand manufacturer uses the same data to monitor Paragraph IV activity on its own portfolio, anticipate settlement negotiation windows, and identify which secondary patents provide the most defensible exclusivity runway. The commercial intelligence function at both ends of the value chain runs on the same underlying LOE data.<\/p>\n\n\n\n

          LOE Alerts and Monitoring: Why Static Databases Fail for Portfolio Management<\/strong><\/h3>\n\n\n\n

          Portfolio-level LOE management requires alerts, not just snapshots. An ANDA filed against one of your products today changes your litigation calendar, your settlement negotiation leverage, and potentially your authorized generic strategy \u2014 immediately. A PTAB IPR petition filed against a secondary patent that was your last LOE barrier effectively moves your expected generic entry date from 2031 to 2025 in a single event.<\/p>\n\n\n\n

          Static databases \u2014 PAT-INFORMED, the raw Orange Book, even a manually built spreadsheet \u2014 do not fire alerts. The intelligence gap between a database search performed once and a monitoring system that tracks Paragraph IV notifications, PTAB petition filings, and settlement disclosures in real time is the difference between reactive and proactive LOE management.<\/p>\n\n\n\n

          \n\n\n\n

          LOE in the Global Context: The $300 Billion Patent Cliff Through 2030<\/strong><\/h2>\n\n\n\n

          The scale of pharmaceutical revenue approaching LOE events makes accurate patent expiry data a financial variable, not just a legal one.<\/p>\n\n\n\n

          Which Blockbuster Drugs Are Approaching LOE and When<\/strong><\/h3>\n\n\n\n

          Between 2025 and 2030, approximately $300 billion in prescription drug revenues will lose patent exclusivity \u2014 roughly one-sixth of the industry’s annual revenue [9]. About 200 drugs will see patent expirations in this window, including around 70 blockbusters generating over $1 billion annually in sales.<\/p>\n\n\n\n

          Specific examples of major LOE events now in progress or approaching:<\/p>\n\n\n\n

            \n
          • Merck’s Januvia (sitagliptin) and Janumet (sitagliptin\/metformin): patent protection lapsed in 2026, generic competition entering the diabetes franchise [10]<\/li>\n\n\n\n
          • Pfizer’s Xeljanz (tofacitinib): immunology drug facing generic entry in 2026 [10]<\/li>\n\n\n\n
          • Bristol-Myers Squibb’s Eliquis (apixaban): among the most closely watched LOE events in cardiology, with BMS’s potential revenue exposure at approximately $38 billion [11]<\/li>\n\n\n\n
          • Merck’s Keytruda (pembrolizumab): immuno-oncology’s best-selling drug globally faces expected loss of patent protection in 2028, prompting Merck’s development of a subcutaneous reformulation to maintain exclusivity through new delivery-method patents [9]<\/li>\n<\/ul>\n\n\n\n

            How Companies Respond to Approaching LOE: Lifecycle Management Strategies<\/strong><\/h3>\n\n\n\n

            When a major drug approaches LOE, brand companies deploy lifecycle management tactics that patent databases must track to remain analytically current:<\/p>\n\n\n\n

            Reformulation generates new composition or formulation patents on modified drug delivery systems, extended-release versions, combination products, or new salt forms. Each new formulation patent filed and listed in the Orange Book creates a new barrier to generic entry \u2014 and a new Paragraph IV challenge target. Merck’s subcutaneous pembrolizumab program illustrates this strategy at scale.<\/p>\n\n\n\n

            New indication filings generate regulatory exclusivity periods (three years for a new indication) that layer protection over an aging CoM patent. Post-approval pediatric studies generate six-month pediatric exclusivity extensions automatically upon completion, without any new patent filing required.<\/p>\n\n\n\n

            Supply and distribution agreements with authorized generics allow brand companies to capture generic market revenue through subsidiary or licensing arrangements while maintaining a pricing umbrella in the brand channel. These agreements often set generic entry dates that bear no relation to any patent expiry date in any database.<\/p>\n\n\n\n

            Revenue at Risk by Company: How LOE Concentration Creates Financial Exposure<\/strong><\/h3>\n\n\n\n

            The patent cliff does not strike all companies equally. By 2026, eight of the 13 largest pharmaceutical firms \u2014 representing 55% of global market value \u2014 could see 30% or more of their revenue exposed to LOE events, with per-company losses ranging from approximately $6 billion to $38 billion [9]. Five of the top 10 pharma companies face more than 50% revenue exposure in this window.<\/p>\n\n\n\n

            DeepCeutix’s analysis of reformulation ROI notes that the revenues from drugs still under patent in 2031 will equal just 23% of 2021 revenues; by 2034, that figure drops to 10% [9]. The reformulation response to the cliff is characterized as the highest-ROI lifecycle management option \u2014 potentially over 1,000% annually on the investment \u2014 precisely because it protects existing revenue rather than replacing it with pre-revenue pipeline assets.<\/p>\n\n\n\n

            \n\n\n\n

            Paragraph IV Certifications and LOE: What the Patent Databases Miss<\/strong><\/h2>\n\n\n\n

            How the Hatch-Waxman Paragraph IV Process Works<\/strong><\/h3>\n\n\n\n

            Under the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman), a generic manufacturer filing an Abbreviated New Drug Application (ANDA) must certify the status of each patent listed in the Orange Book for the reference listed drug (RLD). The four certification options are Paragraph I through IV:<\/p>\n\n\n\n

              \n
            • Paragraph I: No patent information is listed in the Orange Book<\/li>\n\n\n\n
            • Paragraph II: The listed patent has already expired<\/li>\n\n\n\n
            • Paragraph III: The ANDA seeks approval after the patent expires<\/li>\n\n\n\n
            • Paragraph IV: The listed patent is invalid, unenforceable, or will not be infringed by the generic [12]<\/li>\n<\/ul>\n\n\n\n

              A Paragraph IV certification is an act of patent challenge. The brand company has 45 days to file an infringement lawsuit. If it does, a 30-month automatic stay prevents FDA from approving the ANDA during litigation or for 30 months, whichever is shorter. The first generic filer to submit a Paragraph IV ANDA wins 180-day market exclusivity if it prevails or the brand does not sue.<\/p>\n\n\n\n

              In 2025, DOAR’s analysis tracked 320 new ANDA cases across 124 distinct product groups \u2014 an indication of the scale of Paragraph IV activity as the patent cliff accelerates [19].<\/p>\n\n\n\n

              What Happens to LOE When a Paragraph IV Challenge Succeeds?<\/strong><\/h3>\n\n\n\n

              When a generic manufacturer wins a Paragraph IV challenge \u2014 either by court judgment of invalidity or non-infringement, or by the brand company declining to sue \u2014 the challenged patent no longer blocks market entry. The generic can launch before that patent expires. The LOE date for commercial forecasting purposes moves to the date of the successful challenge, not the date of patent expiry in any database.<\/p>\n\n\n\n

              For drugs with heavily litigated Orange Book patent listings, the gap between the nominal patent expiry date in any database and the actual generic entry date can be measured in years in either direction. Generic entry can happen five years before patent expiry on a successful challenge, or three to five years after nominal expiry if secondary patents and litigation holds remain active.<\/p>\n\n\n\n

              The 180-Day Exclusivity Bottleneck: Why First-Filer Status Changes LOE Timing<\/strong><\/h3>\n\n\n\n

              The 180-day first-filer exclusivity period is both the primary financial incentive for Paragraph IV challenges and the principal mechanism by which settlement agreements delay generic competition. When the first generic ANDA filer and the brand company settle \u2014 particularly if the settlement involves a delayed entry date for the generic \u2014 no other generic manufacturer can enter the market until the first filer uses or forfeits its 180-day exclusivity period.<\/p>\n\n\n\n

              A 2010 FTC study found that in the period from 2004 to 2009, 66 settlements involved some form of compensation for delayed generic entry, with 77% of those involving agreements with the first ANDA filer [20]. When a first-filer settlement delays market entry by two years beyond nominal patent expiry, the effectively delayed LOE event multiplies across all subsequent generic entrants \u2014 only PAT-INFORMED and the raw Orange Book are the wrong tools to monitor this, because neither tracks settlement terms.<\/p>\n\n\n\n

              \n\n\n\n

              Biologics and the Purple Book: Why PAT-INFORMED Is Even Less Relevant for Biosimilar LOE<\/strong><\/h2>\n\n\n\n

              The BPCIA Patent Dance and Why It Has No PAT-INFORMED Equivalent<\/strong><\/h3>\n\n\n\n

              For biological products, the Hatch-Waxman framework does not apply. Biosimilar entry is governed by the Biologics Price Competition and Innovation Act (BPCIA), which created a separate 12-year exclusivity period from the date of first licensure of the reference biologic \u2014 independent of any patent expiry. No patent challenge or Orange Book certification is required to trigger this exclusivity; it runs automatically from FDA approval of the reference product.<\/p>\n\n\n\n

              The BPCIA also created the ‘patent dance’: a structured information exchange between the biosimilar applicant and the reference product sponsor that defines which patents will be litigated in a prescribed sequence. The patent dance produces litigation outcomes specific to each biosimilar-reference product pair, meaning LOE dates for biologics are product-specific, applicant-specific, and cannot be read directly from any single database.<\/p>\n\n\n\n

              PAT-INFORMED’s planned expansion to cover complex therapeutics was not implemented as of 2026. Even if biologics were added to PAT-INFORMED, the database structure \u2014 which shows patent grant dates without the regulatory exclusivity layer \u2014 would be insufficient for biosimilar entry analysis without the Purple Book’s reference product exclusivity data and BPCIA litigation tracking.<\/p>\n\n\n\n

              Purple Book LOE Analysis: Reference Product Exclusivity and Biosimilar Launch Timing<\/strong><\/h3>\n\n\n\n

              The FDA’s Purple Book lists all licensed biological products and their reference product exclusivity expiration dates. The 12-year exclusivity period from first licensure is the anchor date for biosimilar market entry planning. A biosimilar developer planning market entry must track the Purple Book exclusivity date, any BPCIA patent dance litigation, the biosimilar’s own regulatory approval timeline, interchangeability status, and competitive biosimilar applications ahead of it in the FDA queue.<\/p>\n\n\n\n

              The global biosimilar market was valued at $26.5 billion in 2024 and is projected to reach $185.1 billion by 2033 [16]. That projected growth is contingent on successful patent clearance through the BPCIA framework \u2014 a process PAT-INFORMED cannot inform at all.<\/p>\n\n\n\n

              \n\n\n\n

              Building a LOE Research Stack: Which Tools to Use at Each Stage<\/strong><\/h2>\n\n\n\n

              The Four-Tool Framework for Complete LOE Analysis<\/strong><\/h3>\n\n\n\n

              No single tool provides a complete LOE picture. Professional LOE analysis requires a stack of complementary resources used in sequence:<\/p>\n\n\n\n

              Step 1: Orange Book (FDA).<\/strong> Start here for all U.S. small-molecule LOE analysis. The Orange Book provides the canonical list of Orange Book-listed patents, PTE-adjusted expiry dates, regulatory exclusivity codes, and NDA application history. It is free, authoritative, and updated monthly. Its limitation is that it shows nothing about ANDA filings against those patents or litigation status.<\/p>\n\n\n\n

              Step 2: DrugPatentWatch.<\/strong> Layer integrated LOE intelligence on top of the Orange Book’s raw data. DrugPatentWatch’s estimated generic entry dates incorporate Paragraph IV filing status, first-filer 180-day exclusivity tracking, ANDA applicant counts, and litigation outcomes into a single time-adjusted estimate. For portfolio-level LOE monitoring with alert capabilities, it is the most purpose-built commercial tool available.<\/p>\n\n\n\n

              Step 3: Federal Court Dockets (PACER or legal databases).<\/strong> For drugs where active Hatch-Waxman litigation is underway, the actual case filings, claim construction orders, and final judgments are the most current and definitive source of information about when generic entry will occur. Court decisions can change LOE dates within weeks of issuance.<\/p>\n\n\n\n

              Step 4: PAT-INFORMED.<\/strong> Use for international patent status verification in non-U.S. markets where you need a quick-reference source for a company-confirmed patent grant date, or where no national patent register equivalent to the Orange Book exists. Useful as a starting point for global freedom-to-operate screening and emerging market generics strategy.<\/p>\n\n\n\n

              When PAT-INFORMED Is the Right Primary Source<\/strong><\/h3>\n\n\n\n

              PAT-INFORMED is the right primary source when the question is explicitly about patent status in a specific non-U.S. jurisdiction for a WHO EML medicine or a drug in its covered therapeutic areas. Examples include: a procurement officer at UNICEF needs to know whether darunavir (HIV antiretroviral) is under patent in Kenya; a global health NGO wants to understand which countries have remaining patent barriers on sacubitril\/valsartan for heart failure treatment in low-income countries; or a research team studying pharmaceutical access wants a multi-country patent status baseline for essential medicines.<\/p>\n\n\n\n

              \n\n\n\n

              Practical LOE Intelligence: Four Drug Examples Where the Tool Distinction Matters<\/strong><\/h2>\n\n\n\n

              Case Example 1: Sofosbuvir (Sovaldi) \u2014 Where PAT-INFORMED Is Actually Useful<\/strong><\/h3>\n\n\n\n

              Sofosbuvir, the Gilead hepatitis C drug sold as Sovaldi, is exactly the kind of medicine PAT-INFORMED was designed to cover: a high-cost essential medicine in a covered therapeutic area. Procurement agencies in Egypt, India, and sub-Saharan Africa have used patent status data for sofosbuvir to determine when generic licensing \u2014 or compulsory licensing \u2014 becomes viable in their markets.<\/p>\n\n\n\n

              PAT-INFORMED can show whether Gilead holds active patents on sofosbuvir in specific national jurisdictions, the grant dates of those patents, and links to the patent texts. For a procurement agency designing a tender, this provides a credible starting point. For U.S. LOE modeling, the Orange Book covers this drug fully and PAT-INFORMED adds nothing.<\/p>\n\n\n\n

              Case Example 2: Sitagliptin (Januvia) \u2014 U.S. LOE Where PAT-INFORMED Falls Short<\/strong><\/h3>\n\n\n\n

              Merck’s sitagliptin, branded as Januvia, illustrates the gap precisely. The diabetes franchise represented several billion dollars in annual Merck revenue as it entered the patent cliff period in 2026. For U.S. analysts modeling Merck’s revenue exposure, the relevant data points were the Orange Book-listed CoM patent expiry, NCE exclusivity status, whether any ANDA filers had achieved first-to-file Paragraph IV status, settlement agreement terms with such filers, and the expected launch timeline for first-wave generics [10].<\/p>\n\n\n\n

              None of these data points appear in PAT-INFORMED. The Orange Book, combined with FDA ANDA filing records and DrugPatentWatch’s integrated monitoring, provides the analysis that actually matters for financial forecasting.<\/p>\n\n\n\n

              Case Example 3: Pembrolizumab (Keytruda) \u2014 A Biologic Beyond PAT-INFORMED’s Scope<\/strong><\/h3>\n\n\n\n

              Merck’s pembrolizumab, the world’s best-selling drug as of the mid-2020s, is a PD-1 checkpoint inhibitor biologic. It lies entirely outside PAT-INFORMED’s practical coverage \u2014 biologics were not added to the database in practice \u2014 and its LOE analysis belongs to the Purple Book-BPCIA framework. Merck’s strategy to develop a subcutaneous formulation covered by new delivery patents creates new patent filings and a new exclusivity stack distinct from the original IV formulation’s LOE timeline [9]. No static database captures this in real time.<\/p>\n\n\n\n

              Case Example 4: Tenofovir Alafenamide \u2014 Global Access Intelligence PAT-INFORMED Supports<\/strong><\/h3>\n\n\n\n

              Tenofovir alafenamide (TAF), an HIV antiretroviral from Gilead, is covered in PAT-INFORMED’s HIV\/AIDS therapeutic area. For a procurement officer in a middle-income country not covered by Medicines Patent Pool licensing, PAT-INFORMED can confirm whether Gilead holds active TAF patents locally and enables a direct inquiry to Gilead through the procurement agency channel. This combination of database search and company inquiry capability is the tool’s most distinctive feature and has no direct equivalent elsewhere for multi-jurisdiction essential medicine procurement.<\/p>\n\n\n\n

              \n\n\n\n

              LOE Forecasting Risk: What Happens When Patent Data Is Incomplete<\/strong><\/h2>\n\n\n\n

              Financial Impact of LOE Miscalculation on Revenue Models<\/strong><\/h3>\n\n\n\n

              Revenue at risk from LOE events is not an abstract measure. By 2026, eight of the 13 largest pharmaceutical firms could see 30% or more of their revenue exposed to LOE events, with per-company losses ranging from approximately $6 billion to $38 billion [9]. A one-year error in a drug’s LOE date translates directly into a one-year error in the model’s generic revenue erosion curve.<\/p>\n\n\n\n

              Post-LOE revenue erosion for small-molecule branded drugs follows a steep decline: generic entry commonly erodes 80-90% of brand unit volume within 12-24 months of first generic launch [16]. In a $2 billion revenue drug, a one-year LOE error produces a billion-dollar timing error in projected revenue before any growth assumptions are applied.<\/p>\n\n\n\n

              Supply Chain and API Planning Tied to LOE Timing<\/strong><\/h3>\n\n\n\n

              LOE timing matters not just for financial modeling but for supply chain planning. Active Pharmaceutical Ingredient (API) manufacturers supplying generic drug companies plan production capacity investments around anticipated LOE windows. A generic API supplier building capacity for first-wave generic entry needs the LOE date with high confidence two to three years in advance to justify capital expenditure.<\/p>\n\n\n\n

              Patent expiry dates from self-reported databases that do not account for PTE, regulatory exclusivity, or pending litigation are not sufficient precision for these supply chain commitments. API suppliers and CDMOs with sophisticated LOE intelligence have a structural cost advantage over those relying on incomplete data sources.<\/p>\n\n\n\n

              What Happens to Pricing When Generic Entry Occurs Earlier Than Modeled<\/strong><\/h3>\n\n\n\n

              When generic entry happens earlier than a brand company modeled \u2014 because a Paragraph IV challenge succeeded or a PTAB IPR invalidated a key blocking patent \u2014 the brand faces immediate price and volume pressure it did not plan for. Commercial teams that had not activated defensive pricing strategies, authorized generic programs, or patient support bridge programs before the unexpected LOE event find themselves responding reactively to competitor dynamics they should have anticipated.<\/p>\n\n\n\n

              The commercial intelligence gap is not just financial. Early LOE events force rapid contracting changes with pharmacy benefit managers, rebate renegotiations with payers, and manufacturing capacity adjustments. Every one of those downstream consequences is more expensive to manage reactively than proactively.<\/p>\n\n\n\n

              \n\n\n\n

              LOE Timeline Tools: How to Build a Multi-Year Patent Expiry Calendar<\/strong><\/h2>\n\n\n\n

              Creating a Drug Patent Expiry Timeline for a Therapeutic Area or Competitor Portfolio<\/strong><\/h3>\n\n\n\n

              Portfolio-level LOE calendars show which drugs in a class or from a competitor lose exclusivity and when. Building one requires systematic collection of per-drug LOE dates, not a single database search.<\/p>\n\n\n\n

              A methodologically sound LOE calendar requires: Orange Book extraction of all listed patents and their PTE-adjusted expiry dates; regulatory exclusivity expiry dates from the same source; ANDA filing counts to assess competitive intensity at each LOE event; active Paragraph IV litigation status for each drug; and historical settlement patterns for comparable drugs to calibrate expected entry timing relative to nominal expiry.<\/p>\n\n\n\n

              PAT-INFORMED can contribute the international dimension: which markets within a therapeutic area retain patent barriers on specific drugs, which are patent-free, and where generic competition is already established. That layer is genuinely useful for a global LOE calendar and is not easily obtained elsewhere without full national patent office searches in multiple jurisdictions.<\/p>\n\n\n\n

              LOE Calendar Data Sources: What to Pull from Each Resource<\/strong><\/h3>\n\n\n\n
              Data Point<\/strong><\/th>Source<\/strong><\/th>Update Frequency<\/strong><\/th><\/tr><\/thead>
              U.S. patent expiry (PTE-adjusted)<\/td>FDA Orange Book<\/td>Monthly<\/td><\/tr>
              U.S. regulatory exclusivity expiry<\/td>FDA Orange Book<\/td>Monthly<\/td><\/tr>
              ANDA filing count and Paragraph IV status<\/td>FDA ANDA database, DrugPatentWatch<\/td>Weekly<\/td><\/tr>
              PTAB IPR petition status<\/td>PTAB docket, DrugPatentWatch<\/td>Real-time<\/td><\/tr>
              Litigation status and outcomes<\/td>PACER, DrugPatentWatch, legal databases<\/td>Real-time<\/td><\/tr>
              Biosimilar exclusivity and Purple Book<\/td>FDA Purple Book<\/td>Monthly<\/td><\/tr>
              Non-U.S. patent status<\/td>PAT-INFORMED, national patent offices, PATENTSCOPE<\/td>Variable<\/td><\/tr>
              Global licensing and voluntary access<\/td>Medicines Patent Pool \/ MedsPaL<\/td>Quarterly<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

              The Annual LOE Calendar Review Process: A Workflow for Commercial Teams<\/strong><\/h4>\n\n\n\n

              Commercial teams at branded pharmaceutical companies typically conduct formal LOE calendar reviews annually with quarterly updates. The annual review establishes the baseline LOE date for each product in the portfolio and each competitor product being tracked. Quarterly updates capture material changes: new ANDA filings against company products, Paragraph IV notices received, PTAB petitions filed, and any litigation outcomes that moved expected entry dates.<\/p>\n\n\n\n

              The quarterly update cycle exists because LOE dates are not stable enough to review annually only. Paragraph IV filings can arrive in any quarter, PTAB institutions happen on the USPTO’s schedule, and settlement negotiations can conclude and become public at any time.<\/p>\n\n\n\n

              \n\n\n\n

              Is PAT-INFORMED Updated? Currency of Data and the Self-Reporting Lag<\/strong><\/h2>\n\n\n\n

              How Current Is PAT-INFORMED Patent Data?<\/strong><\/h3>\n\n\n\n

              Data currency in PAT-INFORMED depends entirely on when participating companies choose to update their submissions. WIPO hosts the data and provides infrastructure; it does not independently maintain or refresh the underlying patent records. A company that files a new patent on a reformulated product, successfully prosecutes a continuation application, or receives a PTE on an existing patent must submit that update to PAT-INFORMED for it to appear.<\/p>\n\n\n\n

              There is no mandatory refresh cycle and no public disclosure of when each company’s data was last updated. For procurement purposes \u2014 determining whether a given essential medicine has any active patent in a specific country \u2014 the self-reporting lag is manageable: the core composition-of-matter patent on an approved medicine does not change frequently, and companies have an incentive to disclose it accurately to avoid procurement disputes.<\/p>\n\n\n\n

              Self-Reporting Lag vs. Orange Book Mandatory Update Requirements<\/strong><\/h3>\n\n\n\n

              The Orange Book, by contrast, requires companies to submit new patent information within 30 days of NDA approval or patent issuance \u2014 a legally mandated update cycle that PAT-INFORMED lacks. Patent information for listing in the Orange Book must be submitted on Form FDA 3542 within 30 days following approval of an NDA or supplemental application [21]. For patents issued after NDA approval, the NDA holder must submit within 30 days of patent issuance to be considered timely filed.<\/p>\n\n\n\n

              This mandatory 30-day submission window means the Orange Book remains current within a predictable lag. PAT-INFORMED has no equivalent obligation, meaning company-submitted data could be months or years out of date for secondary patents and continuation filings.<\/p>\n\n\n\n

              \n\n\n\n

              Patent Term Extensions: The Calculation PAT-INFORMED Cannot Do for You<\/strong><\/h2>\n\n\n\n

              How PTE Works Under 35 U.S.C. \u00a7 156: The Hatch-Waxman Patent Restoration Mechanism<\/strong><\/h3>\n\n\n\n

              Patent Term Extension under the Hatch-Waxman Act is the legislative recognition that drug patents lose effective term during the regulatory review process. The mechanism allows a single U.S. patent covering an approved drug product to be extended by up to five years, subject to a cap of 14 years of post-approval exclusivity.<\/p>\n\n\n\n

              The calculation is: half the time in clinical testing plus all of the FDA review period, reduced by any time the applicant failed to act with due diligence. The USPTO grants PTEs; the FDA provides the regulatory review period data that drives the calculation.<\/p>\n\n\n\n

              PAT-INFORMED shows grant dates and publication dates. It does not show PTEs. For drugs within its covered therapeutic areas, the nominal patent expiry calculable from PAT-INFORMED grant dates will systematically underestimate effective U.S. exclusivity for drugs that received PTEs \u2014 which is most major drug products.<\/p>\n\n\n\n

              Patent Term Restoration vs. Regulatory Exclusivity: Different Mechanisms, Different Calculations<\/strong><\/h3>\n\n\n\n

              Patent Term Extension and regulatory exclusivity are distinct legal mechanisms. PTE extends a patent’s term. NCE exclusivity independently blocks any ANDA filing for five years, regardless of patent status. Both can run simultaneously on the same drug. The effective LOE date is the later of the two to expire \u2014 or the last-to-expire secondary patent if it outlasts both.<\/p>\n\n\n\n

              This interaction explains why some drugs remain free from generic competition years after their composition-of-matter patent expired. If NCE exclusivity runs for five years and the CoM patent expired after three years of effective market life, the NCE exclusivity provides two additional years of protection in the absence of any patent. PAT-INFORMED’s patent-only data structure cannot capture this regulatory exclusivity layer under any circumstances.<\/p>\n\n\n\n

              \n\n\n\n

              PATENTSCOPE and PAT-INFORMED: Using the Link to Full Patent Texts<\/strong><\/h2>\n\n\n\n

              How to Move from PAT-INFORMED to Full Patent Analysis via PATENTSCOPE<\/strong><\/h3>\n\n\n\n

              One of PAT-INFORMED’s practical features is its integration with WIPO’s PATENTSCOPE database. Where available, each patent record in PAT-INFORMED contains a direct link to the full patent text in PATENTSCOPE. This allows a user who identifies a relevant patent grant in PAT-INFORMED to immediately access the claims, description, and prosecution history for that patent.<\/p>\n\n\n\n

              PATENTSCOPE covers PCT (Patent Cooperation Treaty) international applications and the national phase filings of major patent offices. The link from PAT-INFORMED to PATENTSCOPE works only where the patent was filed under the PCT framework and the PATENTSCOPE record is available.<\/p>\n\n\n\n

              Claim Scope Analysis: What Patent Claims Tell You About Generic Strategy<\/strong><\/h3>\n\n\n\n

              Reading the patent claims linked through PAT-INFORMED and PATENTSCOPE provides information that patent grant dates alone do not: the scope of what the patent actually covers. A composition-of-matter claim that covers the active molecule broadly creates a different generic challenge landscape than a formulation claim that covers one specific drug delivery system.<\/p>\n\n\n\n

              Generic manufacturers performing freedom-to-operate analysis must review claim scope, not just expiry dates. A formulation patent can be designed around; a composition-of-matter patent on the active ingredient typically cannot. Understanding which layer of the patent stack poses the highest infringement risk requires claim-level analysis \u2014 accessible via the PAT-INFORMED to PATENTSCOPE link for relevant PCT applications.<\/p>\n\n\n\n

              Limitations of PATENTSCOPE for National Patent Analysis<\/strong><\/h4>\n\n\n\n

              PATENTSCOPE does not cover every national patent office, and national-phase filings are not always fully indexed in a timely way. For pharmaceutical products in countries with developing patent office infrastructure \u2014 parts of Africa, South Asia, Southeast Asia \u2014 PATENTSCOPE coverage may be incomplete. National patent office searches, sometimes requiring local patent attorneys, may be necessary to verify the status that PAT-INFORMED shows.<\/p>\n\n\n\n

              \n\n\n\n

              Evergreening and the Secondary Patent Problem in LOE Analysis<\/strong><\/h2>\n\n\n\n

              How Secondary Patents Extend Drug Exclusivity Beyond CoM Expiry<\/strong><\/h3>\n\n\n\n

              The composition-of-matter patent on a drug’s active ingredient is only one element of the patent landscape around a major branded pharmaceutical product. Companies file additional patents throughout a drug’s commercial life: formulation patents, polymorph patents, method-of-use patents, combination patents, and metabolite patents.<\/p>\n\n\n\n

              DrugPatentWatch’s analysis of device patents in combination products documents that device patents in inhalation and injection delivery systems extend effective exclusivity by 4.7 years on average beyond the CoM patent for combination products [13]. Method-of-use patents with four or more use codes have been associated with a 4.2-year average delay in generic entry relative to CoM expiry.<\/p>\n\n\n\n

              These secondary patents may or may not appear in PAT-INFORMED. The database covers ‘key patents’ as selected and submitted by the company. For a complete patent landscape analysis, especially one that accounts for the full secondary patent stack, PAT-INFORMED is not a substitute for an Orange Book pull combined with a full USPTO prosecution history search.<\/p>\n\n\n\n

              When Is a Secondary Patent ‘Evergreening’ vs. Legitimate Innovation?<\/strong><\/h3>\n\n\n\n

              The term evergreening gets applied broadly in policy debate to any patent filing that extends a drug’s exclusivity beyond its original CoM expiry. A more analytically precise view distinguishes between secondary patents that cover genuine clinical advances \u2014 a new formulation that reduces dosing frequency, a pediatric formulation requiring novel delivery engineering \u2014 and patents on trivial variations designed primarily to create blocking positions.<\/p>\n\n\n\n

              U.S. courts and the USPTO have moved toward tightening this boundary. PTAB’s high IPR institution rate for bio\/pharma patents (73% in FY2024 [14]) reflects the reality that many secondary pharmaceutical patents do not survive rigorous post-grant challenge. Practitioners monitoring LOE events should track PTAB IPR petitions against secondary patents as early indicators of vulnerability in a drug’s exclusivity stack.<\/p>\n\n\n\n

              \n\n\n\n

              Non-U.S. LOE Analysis: Where PAT-INFORMED Adds Real Value<\/strong><\/h2>\n\n\n\n

              Generic Entry Timing in Europe: EMA, SPCs, and the PAT-INFORMED Gap<\/strong><\/h3>\n\n\n\n

              In Europe, the equivalent of a Patent Term Extension is the Supplementary Protection Certificate (SPC). Under EU Regulation 469\/2009, an SPC can extend a medicinal product patent by up to five years from its expiry date, plus an additional six months for pediatric studies. SPCs are granted at the national level by individual EU member state patent offices, creating a jurisdiction-specific extension landscape even within a single regulatory block.<\/p>\n\n\n\n

              PAT-INFORMED shows patent grant dates for European patents and can link to European Patent Office records where applicable. It does not show SPC grant status or SPC expiry dates. For European LOE analysis, PAT-INFORMED’s grant date data is even more likely to understate effective exclusivity than in the U.S. context. European SPC databases must be checked country by country through national patent offices for a complete European LOE picture.<\/p>\n\n\n\n

              Generic Entry in Japan, China, and Emerging Markets<\/strong><\/h3>\n\n\n\n

              Japan has its own patent linkage system under the Pharmaceutical and Medical Devices Act, which links Orange Book-equivalent patent listings to generic drug approval. China built a similar patent linkage system under pharmaceutical patent linkage regulations introduced in 2021. Both operate differently from U.S. Hatch-Waxman.<\/p>\n\n\n\n

              For major pharmaceutical markets outside the U.S. and EU, PAT-INFORMED’s value is primarily confirming whether a key patent was filed and granted in that jurisdiction \u2014 a necessary but not sufficient condition for LOE analysis. Regulatory exclusivity periods, data exclusivity protections, and patent linkage challenge mechanisms vary by country and require market-specific expertise beyond what any single global database provides.<\/p>\n\n\n\n

              Using PAT-INFORMED for Emerging Market Tender Strategy<\/strong><\/h4>\n\n\n\n

              For pharmaceutical companies managing tender participation in middle-income markets \u2014 Brazil, India, South Africa, Mexico, Indonesia \u2014 PAT-INFORMED provides a useful pre-engagement check. Before committing to a competitive tender in any of these markets, confirming active patent status via PAT-INFORMED takes minutes and can prevent the costly error of submitting a brand price for a drug that is effectively patent-free in that jurisdiction, or the opposite error of submitting a generic-comparable price for a drug still under active patent protection.<\/p>\n\n\n\n

              \n\n\n\n

              The Inquiry Channel: Using PAT-INFORMED’s Unique Company Contact Feature<\/strong><\/h2>\n\n\n\n

              Who Can Use the PAT-INFORMED Procurement Agency Inquiry Feature?<\/strong><\/h3>\n\n\n\n

              PAT-INFORMED’s second-tier feature is restricted to bona fide procurement agencies. Company responses through this channel are not confidential, which means the information disclosed can be used in public procurement decisions. WIPO and IFPMA act as intermediaries, forwarding qualified requests to the relevant companies. Private-sector pharmaceutical companies, hedge funds, and commercial intelligence professionals do not qualify.<\/p>\n\n\n\n

              What Information Can Be Requested Through the Inquiry Channel?<\/strong><\/h3>\n\n\n\n

              The inquiry channel allows procurement agencies to ask questions beyond what the public database displays: pending patent applications not yet granted, the company’s views on patent validity or enforceability in specific jurisdictions, clarification of patent scope relevant to a generic product the agency is considering procuring, and licensing availability for the market in question.<\/p>\n\n\n\n

              In markets where no formal patent linkage mechanism exists, this documented company disclosure can serve as the procurement agency’s due diligence record if a later dispute arises about whether a generic procurement decision was made in good faith with knowledge of the patent landscape.<\/p>\n\n\n\n

              Practical Limitations of the Inquiry Channel for Time-Sensitive Procurement<\/strong><\/h3>\n\n\n\n

              The inquiry channel involves WIPO and IFPMA as intermediaries, which adds time to the response cycle relative to a direct company contact. For procurement agencies working against tender deadlines, the inquiry channel may not provide responses quickly enough to inform a time-sensitive decision. Front-loading patent status research \u2014 checking PAT-INFORMED early in the procurement planning cycle rather than at the tender stage \u2014 is the standard recommendation for agencies using the platform effectively.<\/p>\n\n\n\n

              \n\n\n\n

              Key Takeaways<\/strong><\/h2>\n\n\n\n
                \n
              • PAT-INFORMED is a WIPO-IFPMA partnership database launched in 2018, designed specifically for procurement agencies in global health \u2014 not for U.S. pharmaceutical competitive intelligence or financial LOE modeling.<\/li>\n\n\n\n
              • The database contains company-submitted patent grant dates and publication numbers for 169 INNs across six therapeutic areas plus WHO EML products. It does not display LOE dates as a formatted output.<\/li>\n\n\n\n
              • A nominal patent expiry date calculable from PAT-INFORMED grant dates is not an LOE date. True U.S. LOE dates require PTE-adjusted expiry, regulatory exclusivity stacking, Paragraph IV litigation status, and settlement agreement tracking \u2014 none of which PAT-INFORMED provides.<\/li>\n\n\n\n
              • For U.S. LOE analysis, the FDA Orange Book is the starting point for patent and exclusivity data. DrugPatentWatch provides integrated LOE intelligence including estimated generic entry dates, ANDA filing tracking, and litigation monitoring.<\/li>\n\n\n\n
              • PAT-INFORMED is the right tool when the question is patent status in specific non-U.S. markets for covered therapeutic areas \u2014 particularly for essential medicines procurement in low- and middle-income countries.<\/li>\n\n\n\n
              • The database covers only small-molecule drugs in practice. Biologic LOE analysis belongs to the Purple Book-BPCIA framework, entirely outside PAT-INFORMED’s scope.<\/li>\n\n\n\n
              • MedsPaL, operated by the Medicines Patent Pool, is PAT-INFORMED’s closest alternative for global access research, with data sourcing from national patent offices rather than company submissions, and a narrower drug focus.<\/li>\n\n\n\n
              • PAT-INFORMED’s unique value is its inquiry channel: verified procurement agencies can obtain direct company responses about patent status, pending applications, and licensing availability.<\/li>\n\n\n\n
              • PTAB IPR proceedings institute against 73% of bio\/pharma petitions submitted in FY2024, with a 70% all-claims invalidation rate \u2014 making active PTAB monitoring essential for any serious LOE analysis, and entirely invisible in PAT-INFORMED.<\/li>\n\n\n\n
              • Between 2025 and 2030, approximately $300 billion in global pharmaceutical revenue faces LOE events. At that financial scale, the difference between a correct and incorrect LOE date is measured in billions of dollars per year of forecasting error.<\/li>\n<\/ul>\n\n\n\n
                \n\n\n\n

                Frequently Asked Questions<\/strong><\/h2>\n\n\n\n

                1. Does PAT-INFORMED show when a drug’s patent expires?<\/strong><\/h3>\n\n\n\n

                PAT-INFORMED shows patent grant dates and publication dates. From the grant date and the relevant national patent term (typically 20 years from filing), you can calculate a nominal expiry date. It does not display a formatted expiry date field, and it does not account for Patent Term Extensions, supplementary protection certificates in Europe, or regulatory exclusivity periods. Use the FDA Orange Book for U.S. patent expiry dates.<\/p>\n\n\n\n

                2. Can I use PAT-INFORMED to find U.S. drug patent expiry dates?<\/strong><\/h3>\n\n\n\n

                Technically yes \u2014 you can find U.S. patent grant data for covered drugs in PAT-INFORMED’s six therapeutic areas. But the FDA Orange Book is the authoritative source for U.S. patent expiry dates because it is PTE-adjusted, lists all Orange Book-listed patents, and includes regulatory exclusivity codes. Use the Orange Book for U.S. LOE analysis.<\/p>\n\n\n\n

                3. Is PAT-INFORMED the same as the Orange Book?<\/strong><\/h3>\n\n\n\n

                No. The Orange Book is a U.S.-only, legally mandated, FDA-administered database linking approved NDA drugs to their patents and regulatory exclusivities. PAT-INFORMED is a voluntary, company-submitted, WIPO-hosted database covering global patent status for a limited set of essential medicines. WIPO describes PAT-INFORMED as ‘globalizing the concept of the Orange Book’ \u2014 but the analogy holds only for the basic function of linking medicines to patents, not the legal framework, completeness, or exclusivity data.<\/p>\n\n\n\n

                4. What is the difference between PAT-INFORMED and MedsPaL?<\/strong><\/h3>\n\n\n\n

                Both target global medicine access, but they differ in data source. PAT-INFORMED relies entirely on voluntary company submissions. MedsPaL draws data from national patent offices, public licensing agreements, and regulatory data exclusivity information. MedsPaL focuses specifically on HIV, tuberculosis, hepatitis C, and other essential medicines in low- and middle-income countries and integrates Medicines Patent Pool licensing status, which PAT-INFORMED does not.<\/p>\n\n\n\n

                5. Does PAT-INFORMED cover biologics and biosimilar LOE?<\/strong><\/h3>\n\n\n\n

                Not in practice. A planned expansion to complex therapeutics was not implemented as of 2026. Biosimilar LOE analysis requires the FDA Purple Book for reference product exclusivity dates and BPCIA patent dance litigation tracking \u2014 both entirely outside PAT-INFORMED’s scope and framework. The global biosimilar market’s projected growth to $185 billion by 2033 depends on BPCIA navigation, not PAT-INFORMED.<\/p>\n\n\n\n

                6. Can pharmaceutical companies use PAT-INFORMED for competitive intelligence?<\/strong><\/h3>\n\n\n\n

                The public database is open to anyone, including commercial pharmaceutical companies, for the basic patent grant data it displays. However, the inquiry channel to companies is restricted to procurement agencies. For competitive intelligence purposes, PAT-INFORMED is a limited resource \u2014 useful for non-U.S. patent status checks on competitor products in its covered therapeutic areas, but insufficient for U.S. LOE modeling or generic entry forecasting without integration with Orange Book and litigation data.<\/p>\n\n\n\n

                7. How do I find the true LOE date for a drug in the United States?<\/strong><\/h3>\n\n\n\n

                Start with the FDA Orange Book to identify all listed patents and their PTE-adjusted expiry dates, plus regulatory exclusivity codes. Then check the FDA ANDA database and DrugPatentWatch for Paragraph IV filing status, active litigation, and estimated generic entry dates. Monitor PTAB IPR dockets for any post-grant challenges against listed patents. The true LOE date reflects the last expiring barrier \u2014 patent, exclusivity, active litigation stay, or serial litigation continuation \u2014 not any single date from a single source.<\/p>\n\n\n\n

                8. What happens to generic drug entry when a Paragraph IV challenge succeeds?<\/strong><\/h3>\n\n\n\n

                A successful Paragraph IV challenge allows the first ANDA filer to launch generics before the challenged patent’s nominal expiry date, subject to any remaining regulatory exclusivity. The first successful Paragraph IV filer typically earns 180-day marketing exclusivity, during which no other generic can launch. In 2025, 320 new ANDA cases across 124 distinct product groups tracked Paragraph IV activity at scale, illustrating the frequency with which LOE dates move from patent database to litigation outcome.<\/p>\n\n\n\n

                9. How should a procurement agency in a developing country use PAT-INFORMED?<\/strong><\/h3>\n\n\n\n

                Search by INN and target country to identify whether participating companies have active patent grants in that jurisdiction. Use the results to confirm patent status and estimate approximate expiry from grant date. If additional clarity is needed, use the platform’s inquiry channel to contact the company directly. Cross-reference findings against MedsPaL and the Medicines Patent Pool’s licensing database to check whether voluntary licensing arrangements already cover the market you are procuring for.<\/p>\n\n\n\n

                10. Are the patent expiry dates in PAT-INFORMED legally binding?<\/strong><\/h3>\n\n\n\n

                No. PAT-INFORMED explicitly states that it is ‘not a tool to provide Freedom to Operate analysis.’ The data is provided by companies voluntarily and is not independently verified by WIPO or any patent authority. It provides a starting point for patent status assessment, not a legal opinion. Any procurement decision or market entry strategy that relies on patent data from PAT-INFORMED should be verified through formal patent office searches and legal advice before commitment.<\/p>\n\n\n\n

                \n\n\n\n

                Sources<\/strong><\/h2>\n\n\n\n
                  \n
                1. IFPMA. (2018, September). WIPO and IFPMA launch new online patent-search resource to help health agencies procure medicines.<\/em> IFPMA Press Release. https:\/\/www.ifpma.org\/news\/wipo-and-ifpma-launch-new-online-patent-search-resource-to-help-health-agencies-procure-medicines\/<\/li>\n\n\n\n
                2. WIPO Magazine. (2018). Pat-INFORMED: A new tool for drug procurement.<\/em> World Intellectual Property Organization. https:\/\/www.wipo.int\/en\/web\/wipo-magazine\/articles\/pat-informed-a-new-tool-for-drug-procurement-40528<\/li>\n\n\n\n
                3. IFPMA. (2026). Pat-INFORMED initiative overview.<\/em> International Federation of Pharmaceutical Manufacturers and Associations. https:\/\/www.ifpma.org\/initiatives\/pat-informed\/<\/li>\n\n\n\n
                4. WIPO Magazine. (2018). Pat-INFORMED: A new tool for drug procurement.<\/em> World Intellectual Property Organization. https:\/\/www.wipo.int\/en\/web\/wipo-magazine\/articles\/pat-informed-a-new-tool-for-drug-procurement-40528<\/li>\n\n\n\n
                5. WIPO. (n.d.). Pat-INFORMED frequently asked questions.<\/em> World Intellectual Property Organization. https:\/\/www.wipo.int\/pat-informed\/en\/faqs\/<\/li>\n\n\n\n
                6. DrugPatentWatch. (2026, April). Why Google Patents is not a good solution to identify drug patents.<\/em> thinkBiotech LLC. https:\/\/www.drugpatentwatch.com\/blog\/why-google-patents-is-not-a-good-solution-to-identify-drug-patents\/<\/li>\n\n\n\n
                7. DrugPatentWatch. (2026, March). Drug patent expiration: The complete strategic guide to loss of exclusivity.<\/em> thinkBiotech LLC. https:\/\/www.drugpatentwatch.com\/blog\/the-impact-of-drug-patent-expiration-financial-implications-lifecycle-strategies-and-market-transformations\/<\/li>\n\n\n\n
                8. DrugPatentWatch. (2026, February). Patent expiration dates: The calendar every pharmaceutical investor watches.<\/em> thinkBiotech LLC. https:\/\/www.drugpatentwatch.com\/blog\/patent-expiration-dates-the-calendar-every-pharmaceutical-investor-watches\/<\/li>\n\n\n\n
                9. DeepCeutix. (2026, February). $300 billion in pharma revenue loses patent protection by 2030.<\/em> DeepCeutix Strategic Briefings. https:\/\/deepceutix.com\/insights\/patent-cliff-reformulation<\/li>\n\n\n\n
                10. IntuitionLabs. (2026, May). Drug patents expiring in 2026: A comprehensive guide.<\/em> https:\/\/intuitionlabs.ai\/articles\/drug-patent-expirations-2026<\/li>\n\n\n\n
                11. Drug Discovery News. (2026, February). Blockbuster drugs face a massive patent cliff in 2026.<\/em> https:\/\/www.drugdiscoverynews.com\/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019<\/li>\n\n\n\n
                12. Fish & Richardson. (2022). Orange Book 101: The FDA’s official register of drugs.<\/em> https:\/\/www.fr.com\/insights\/ip-law-essentials\/orange-book-101\/<\/li>\n\n\n\n
                13. DrugPatentWatch. (2019). Is patent evergreening restricting access to medicine-device combination products?<\/em> thinkBiotech LLC. https:\/\/www.drugpatentwatch.com\/blog\/is-patent-evergreening-restricting-access-to-medicine-device-combination-products\/<\/li>\n\n\n\n
                14. PTAB Law Blog. (2025, January). Trial statistics trends at the PTAB: 2024 edition.<\/em> https:\/\/www.ptablaw.com\/2025\/01\/06\/trial-statistics-trends-at-the-ptab-2024-edition\/<\/li>\n\n\n\n
                15. IPWatchdog. (2025, July). Perspectives on the PTAB’s 70% all claims invalidation rate.<\/em> https:\/\/ipwatchdog.com\/2025\/07\/02\/perspectives-ptabs-70-claims-invalidation-rate\/<\/li>\n\n\n\n
                16. DrugPatentWatch. (2026, March). The Patent Trial and Appeal Board: The definitive analyst’s guide to IPR strategy.<\/em> thinkBiotech LLC. https:\/\/www.drugpatentwatch.com\/blog\/understanding-the-patent-trial-and-appeal-board-ptab-a-comprehensive-overview\/<\/li>\n\n\n\n
                17. USPTO. (2025, August). PTAB trial statistics August 2025.<\/em> United States Patent and Trademark Office. https:\/\/prod-web-alb-tg.uspto.gov\/sites\/default\/files\/documents\/Trial_Stats_Aug2025_508.pdf<\/li>\n\n\n\n
                18. Hwang, T., Haberman, M., & Kesselheim, A. S. (2025). Serial patent litigation: An emerging strategy to delay entry of generic competition.<\/em> PubMed Central. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC12757684\/<\/li>\n\n\n\n
                19. DOAR. (2026, February). 2025 in review: Analyzing Hatch-Waxman litigation trends.<\/em> https:\/\/www.doar.com\/insights\/2025-in-review-analyzing-hatch-waxman-litigation-trends\/<\/li>\n\n\n\n
                20. Cotter, T. F. (2011). Hatch-Waxman patent litigation and inter partes review.<\/em> University of Alabama School of Law. http:\/\/law.ua.edu\/wp-content\/uploads\/2011\/07\/Hatch-Waxman-Patent-Litigation-and-Inter-Partes-Review.pdf<\/li>\n\n\n\n
                21. FDA. (n.d.). Frequently asked questions on patents and exclusivity.<\/em> U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/frequently-asked-questions-patents-and-exclusivity<\/li>\n<\/ol>\n\n\n\n

                  <\/p>\n","protected":false},"excerpt":{"rendered":"

                  The short answer is: yes, you can use PAT-INFORMED to find drug patent information, including grant dates and expiry dates […]<\/p>\n","protected":false},"author":1,"featured_media":39051,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39029","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39029"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39029\/revisions"}],"predecessor-version":[{"id":39312,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39029\/revisions\/39312"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39051"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}